Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non Operating Investment Income for 7 consecutive years, with $42000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Investment Income rose 101.56% to $42000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $427000.0, a 41.59% decrease, with the full-year FY2025 number at $427000.0, down 41.59% from a year prior.
  • Non Operating Investment Income was $42000.0 for Q4 2025 at Intellia Therapeutics, down from $337000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $5.1 million in Q4 2022 to a low of -$5.1 million in Q1 2022.
  • A 5-year average of -$50947.4 and a median of -$161000.0 in 2021 define the central range for Non Operating Investment Income.
  • Biggest YoY gain for Non Operating Investment Income was 715.53% in 2022; the steepest drop was 93100.0% in 2022.
  • Intellia Therapeutics' Non Operating Investment Income stood at -$2.0 million in 2021, then skyrocketed by 359.82% to $5.1 million in 2022, then crashed by 129.73% to -$1.5 million in 2023, then crashed by 78.63% to -$2.7 million in 2024, then surged by 101.56% to $42000.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Non Operating Investment Income are $42000.0 (Q4 2025), $337000.0 (Q3 2025), and -$404000.0 (Q2 2025).